Get to know our clinical trials
A Phase 3 Trial to compare IV BCV versus IV CDV for study treatment of adenovirus viremia after allo-HCT.
THE OBJECTIVE OF THE STUDY IS TO EVALUATE THE EFFICACY AND SAFETY OF IV BCV VERSUS IV CDV IN PATIENTS WITH ADENOVIRUS VIREMIA AFTER ALLOGENEIC HCT.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- A PHASE 3, MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY ON THE EFFICACY AND SAFETY OF INTRAVENOUS BRINCIDOFOVIR VERSUS INTRAVENOUS CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC AND ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOGENEIC HCT).
- Code EudraCT: 2025-521903-28
- Protocol number: BCV-PA02
- Promoter: Symbio Pharmaceuticals
- Molecule/Drug: Brincidofovir
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.